← GPCalc

NICE Type 2 Diabetes Calculator

NICE NG28 Type 2 diabetes in adults: management (medicines update 18 Feb 2026) · with NG203, NG238, NG136 and MHRA safety advice

Scenario

Patient

HbA1c target will appear here.

Comorbidities

Before SGLT2 inhibitors

Current medicines

NICE-recommended plan

Enter age and HbA1c to see the plan.

Decision support only, based on NICE NG28 (February 2026 medicines update) as summarised by NICE's visual pathways and published summaries, with BNF/MHRA safety advice. Recommendation numbers changed in 2026 – check the full guideline. It does not replace clinical judgement, the SPC or local formularies.

Quick reference

HbA1c targets
SituationAim
Lifestyle, or drugs not associated with hypoglycaemia48 mmol/mol (6.5%)
On a drug associated with hypoglycaemia (sulfonylurea, insulin)53 mmol/mol (7.0%)
HbA1c rises to 58 (7.5%) or more on treatmentReinforce lifestyle and adherence, intensify, aim for 53

Agree an individual target. Relax for reduced life expectancy, high hypoglycaemia risk (falls, impaired awareness, driving) or significant comorbidity, especially older or frail people. Measure HbA1c every 3–6 months until stable, then 6-monthly. Targets retained in the 2026 update.

2026 drug pathways
PathwayInitialThen
StandardMetformin MR + SGLT2iDPP-4i → SU, pioglitazone or insulin
ObesityMetformin MR + SGLT2iConsider GLP-1 RA or tirzepatide (after ≥3 months) – else DPP-4i → SU, pioglitazone or insulin
ASCVDMetformin MR + SGLT2i + sc semaglutide (≤1 mg weekly)SU, pioglitazone or insulin
Heart failureMetformin MR + SGLT2iDPP-4i → SU or insulin (no pioglitazone)
CKDeGFR >30: metformin MR (≤1 g/day if eGFR <45) + SGLT2i; eGFR 20–30: DPP-4i + dapagliflozin/empagliflozin; eGFR <20: DPP-4i, pioglitazone or insulinPioglitazone, SU (eGFR >30) or insulin. GLP-1 RA/tirzepatide not recommended for CKD
Early onset (<40)Consider metformin MR + SGLT2i + GLP-1 RA or tirzepatideDPP-4i if GLP-1/tirzepatide not tolerated → SU, pioglitazone or insulin
FrailtyMetformin MR; SGLT2i only if frailty doesn't raise adverse-event riskDPP-4i → pioglitazone, SU or insulin; minimise polypharmacy

Several comorbidities: discuss which to prioritise. Don't combine a DPP-4i with a GLP-1 RA or tirzepatide. Continue SGLT2i for cardiorenal benefit even if glucose lowering is limited.

Safety checks
  • SGLT2i: check for previous DKA, dehydration/volume depletion and ketogenic diets; address modifiable DKA risks; don't start during intercurrent illness; sick-day rules and ketone advice (MHRA); warn about genital infection and Fournier's gangrene
  • GLP-1 RA / tirzepatide: recommended GLP-1 RAs are liraglutide, dulaglutide, oral semaglutide and sc semaglutide up to 1 mg. Stop if BMI <18.5, or if not helping glycaemic or weight targets unless used for CV benefit. Tell the hospital eye service before rapid HbA1c lowering in retinopathy. Warn about NAION (urgent ophthalmology for sudden visual loss), pancreatitis, and pregnancy/contraception (MHRA)
  • Metformin: modified-release first (standard-release if liquid/crushed needed). eGFR <45: maximum 1 g/day; don't start if eGFR <30
  • Pioglitazone: not in heart failure; avoid with bladder cancer history or uninvestigated haematuria (BNF/MHRA)
  • Sulfonylurea / insulin: hypoglycaemia education, DVLA advice, capillary glucose monitoring
Insulin
  • Structured programme with support from a trained healthcare professional; discuss continuing cardiorenal and weight-reducing medicines
  • Start once- or twice-daily basal insulin; consider adding short- or rapid-acting (or premixed) insulin if HbA1c ≥75 mmol/mol
  • Choose the lowest-cost suitable insulin, including biosimilars for new starts
  • GLP-1 RAs can now be combined with insulin in primary care
Annual review checklist
  • HbA1c, BP (hypertension calculator), lipids and QRISK3 (lipid calculator)
  • eGFR and urine ACR (CKD calculator)
  • Foot risk assessment, diabetic eye screening, weight/BMI, smoking
  • Structured education at diagnosis and annually; weight-loss target 5–10% if overweight
  • Don't offer aspirin or clopidogrel for primary prevention; ask about periodontitis and dental checks
Lifestyle advice & patient leaflet
  • Structured education (e.g. DESMOND, X-PERT, digital programmes) at diagnosis, reinforced annually
  • Healthy eating as for the general population; individual advice on carbohydrate, weight and alcohol
  • Initial weight-loss target of 5–10% if overweight; physical activity
  • Smoking cessation; sick-day rules; driving and hypoglycaemia if on SU/insulin